KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Retained Earnings: 2013-2024

Historic Retained Earnings for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to -$899.5 million.

  • Xenon Pharmaceuticals' Retained Earnings fell 36.74% to -$1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 billion, marking a year-over-year decrease of 36.74%. This contributed to the annual value of -$899.5 million for FY2024, which is 35.23% down from last year.
  • According to the latest figures from FY2024, Xenon Pharmaceuticals' Retained Earnings is -$899.5 million, which was down 35.23% from -$665.1 million recorded in FY2023.
  • Xenon Pharmaceuticals' Retained Earnings' 5-year high stood at -$278.5 million during FY2020, with a 5-year trough of -$899.5 million in FY2024.
  • Over the past 3 years, Xenon Pharmaceuticals' median Retained Earnings value was -$665.1 million (recorded in 2023), while the average stood at -$682.5 million.
  • Data for Xenon Pharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 37.78% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Retained Earnings stood at -$278.5 million in 2020, then decreased by 28.32% to -$357.4 million in 2021, then plummeted by 35.08% to -$482.7 million in 2022, then plummeted by 37.78% to -$665.1 million in 2023, then tumbled by 35.23% to -$899.5 million in 2024.